Literature DB >> 21133798

Inhaler devices: what remains to be done?

Ian J Smith1, John Bell, Nic Bowman, Mark Everard, Stephen Stein, Jeffry G Weers.   

Abstract

The 1000 Years of Pharmaceutical Aerosols Conference convened posing the question; "what remains to be done?" When applying this question to the topic of inhaler devices, two hugely different perspectives could be taken. On the one hand, it could be argued that because there is an array of delivery systems available and the industry, prescribing physicians and patients alike have considerable choice, why would we believe it necessary to do anything further? On the other hand, as an industry, we are constantly reminded by our "customers" that the inhaler devices available are less than adequate, and in some cases woefully inadequate, that they are not "patient" friendly, not intuitive to use and importantly do nothing to encourage the patient to take the medication as intended and as prescribed. So, taking the second point of view as more reflective of reality--the Voice of the Customer--our starting point must be that there is still much to do in the field of inhaler devices. The purpose of this article is to outline some key basic requirements for inhaler design and perhaps to question some of the entrenched thinking that has pervaded inhaler product design for too many years.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21133798     DOI: 10.1089/jamp.2010.0853

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  17 in total

1.  Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways.

Authors:  P Worth Longest; Geng Tian; Ross L Walenga; Michael Hindle
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

2.  Development of an Inline Dry Powder Inhaler for Oral or Trans-Nasal Aerosol Administration to Children.

Authors:  Dale Farkas; Michael Hindle; Serena Bonasera; Karl Bass; Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-08-29       Impact factor: 2.849

3.  Targeting aerosol deposition to and within the lung airways using excipient enhanced growth.

Authors:  Geng Tian; P Worth Longest; Xiang Li; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-01-03       Impact factor: 2.849

4.  Development of high efficiency ventilation bag actuated dry powder inhalers.

Authors:  Srinivas R B Behara; P Worth Longest; Dale R Farkas; Michael Hindle
Journal:  Int J Pharm       Date:  2014-02-07       Impact factor: 5.875

5.  Influence of Formulation Factors on the Aerosol Performance of Suspension and Solution Metered Dose Inhalers: A Systematic Approach.

Authors:  Poonam Sheth; Dennis Sandell; Denise S Conti; Jay T Holt; Anthony J Hickey; Bhawana Saluja
Journal:  AAPS J       Date:  2017-06-07       Impact factor: 4.009

6.  Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design.

Authors:  Dale R Farkas; Michael Hindle; P Worth Longest
Journal:  Ann Biomed Eng       Date:  2015-05-19       Impact factor: 3.934

7.  Development of an Inline Dry Powder Inhaler That Requires Low Air Volume.

Authors:  Dale Farkas; Michael Hindle; P Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-12-20       Impact factor: 2.849

8.  Aerodynamic factors responsible for the deaggregation of carrier-free drug powders to form micrometer and submicrometer aerosols.

Authors:  P Worth Longest; Yoen-Ju Son; Landon Holbrook; Michael Hindle
Journal:  Pharm Res       Date:  2013-03-08       Impact factor: 4.200

9.  Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations.

Authors:  Srinivas R B Behara; P Worth Longest; Dale R Farkas; Michael Hindle
Journal:  J Pharm Sci       Date:  2013-12-04       Impact factor: 3.534

10.  Development of a high efficiency dry powder inhaler: effects of capsule chamber design and inhaler surface modifications.

Authors:  Srinivas R B Behara; Dale R Farkas; Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2013-08-16       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.